Vofatamab（Cat No.:I042213）is an investigational monoclonal antibody targeting the ephrin type-A receptor 2 (EphA2), a protein involved in tumor progression and metastasis. EphA2 is overexpressed in various cancers, including non-small cell lung cancer, ovarian cancer, and breast cancer, contributing to tumor growth and immune evasion. By binding to EphA2, Vofatamab aims to inhibit tumor cell growth, reduce metastasis, and enhance immune system activity against cancer cells. Clinical trials are underway to evaluate its safety, efficacy, and potential use in combination with other cancer therapies to improve treatment outcomes.
